<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863265</url>
  </required_header>
  <id_info>
    <org_study_id>CANUSU-phyto3</org_study_id>
    <secondary_id>R01HL050420</secondary_id>
    <nct_id>NCT00863265</nct_id>
  </id_info>
  <brief_title>Phytosterols, Ezetimibe, and Cholesterol Metabolism</brief_title>
  <acronym>Phyteaux-III</acronym>
  <official_title>Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Utah State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but appear
      to have different mechanisms of action. The investigators hypothesis is that phytosterols and
      ezetimibe given together will block cholesterol absorption nearly completely. The
      investigators will perform a randomized, placebo-controlled crossover feeding study in 25
      subjects with greater than ideal levels of LDL cholesterol who do not require
      anti-cholesterol drug treatment. Subjects will consume a baseline diet provided by a feeding
      center that is deficient in phytosterols for three periods of 21 days in random order. During
      period I placebo phytosterols and placebo ezetimibe will be given; during period II placebo
      phytosterols and active ezetimibe will be given; during period III active phytosterols and
      active ezetimibe will be given. Study endpoints are fecal cholesterol excretion and percent
      cholesterol absorption determined by gas chromatography/mass spectrometry, circulating
      phytosterol levels and circulating LDL cholesterol levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol Absorption and Excretion</measure>
    <time_frame>At the end of week 3 on each diet</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>At the end of week 3 on each diet</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Phytosterol-Deficient Diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phytosterol-deficient diet plus ezetimibe placebo plus phytosterol placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet Plus Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phytosterol-deficient diet plus 10 mg/day of ezetimibe plus phytosterol placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet Plus Ezetimibe plus Phytosterols</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phytosterol-deficient diet plus 10 mg/day of ezetimibe plus 2000 mg/day of phytosterols.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols</intervention_name>
    <description>Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.</description>
    <arm_group_label>Phytosterol-Deficient Diet</arm_group_label>
    <arm_group_label>Diet Plus Ezetimibe</arm_group_label>
    <arm_group_label>Diet Plus Ezetimibe plus Phytosterols</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of any race or ethnicity between 18 to 80 years of age;

          -  Body mass index between 20 - 35 kg/m2;

          -  LDL-cholesterol between 130 - 189 mg/dL based on the average of duplicate screening
             measures. If the two LDL-C levels differ by more than 30 mg/dL, a third test will be
             scheduled with all three results averaged;

          -  Free of chronic disease;

          -  Willing to eat only the foods that are provided by the Center during the diet periods;

          -  Willing to abstain from the consumption of alcohol for 48-hours prior to blood draw
             days;

          -  Willing to drink no more than 5 cups of caffeine-containing beverages a day.

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 80 years;

          -  Based on duplicate screening laboratory values: 1)LDL-C &gt;=190 mg/dL; 2)TG &gt;=250
             mg/dL;3)blood pressure &gt;= 160 mm Hg systolic or 95 mm Hg diastolic;

          -  Documented presence of atherosclerotic disease;

          -  Diabetes mellitus;

          -  Renal, hepatic, endocrine, gastrointestinal, hematological or other systemic disease;

          -  Body mass index &gt; 35;

          -  For women, pregnancy, breast feeding or postpartum &lt; 6 months;

          -  For women, peri-menopausal;

          -  For women, sexually active but not practicing effective birth control methods;

          -  History of drug or alcohol abuse;

          -  History of depression or mental illness requiring treatment or medication within the
             last 6 months;

          -  multiple food allergies or significant food preferences or restrictions that would
             interfere with diet adherence;

          -  Chronic use of over-the-counter medication which would interfere with study endpoints
             including laxatives and antacids;

          -  Lifestyle or schedule incompatible with the study protocol;

          -  Planned continued use of dietary supplements through the study trial;

          -  Taking any lipid-lowering, or other medications known to affect blood cholesterol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Ostlund, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Advance Nutrition at Utah State University</name>
      <address>
        <city>Logan</city>
        <state>Utah</state>
        <zip>84322-4715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lin X, Racette SB, Lefevre M, Ma L, Spearie CA, Steger-May K, Ostlund RE Jr. Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans. Circulation. 2011 Aug 2;124(5):596-601. doi: 10.1161/CIRCULATIONAHA.110.006692. Epub 2011 Jul 18.</citation>
    <PMID>21768544</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <last_update_submitted>May 2, 2012</last_update_submitted>
  <last_update_submitted_qc>May 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phytosterols</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Cholesterol Excretion</keyword>
  <keyword>Cholesterol Absorption</keyword>
  <keyword>Diet</keyword>
  <keyword>Mass Spectrometry</keyword>
  <keyword>Deuterium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 28, 2018</submitted>
    <returned>February 26, 2018</returned>
    <submitted>March 1, 2018</submitted>
    <returned>March 28, 2018</returned>
    <submitted>April 25, 2018</submitted>
    <returned>May 25, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

